Novo Nordisk Announced The company announced plans Monday to build a $4.1 billion facility in North Carolina as demand for its popular weight-loss drugs has increased in recent months.
The plant will be the Danish company’s second fill and finish manufacturing facility in Clayton, North Carolina, and its fourth overall in the region.
Novo Nordisk, known for the weight-loss and diabetes drugs Wegovy and Ozempic, said in a statement that the new facility will expand by more than 56 acres and add 1.4 million square feet of production space, double the combined size of its other three facilities in North Carolina.
The life sciences investment in Novo Nordisk marks the largest investment in state history. SaidThe company said it plans to hire 1,000 new employees, in addition to 2,500 others in the region.
Construction of the facility is scheduled to be completed in stages between 2027 and 2029, with “initial ground-clearing and foundation works already underway,” the company said.
According to a Novo Nordisk press release, the goal is to expand the company’s “manufacturing capacity for current and future injectable treatments for people living with obesity and other serious chronic diseases.”
“It took a century to reach 40 million patients, but with this expansion and our continued investment in global production, Novo Nordisk is building the capacity to serve millions more people with serious chronic diseases in the future,” Lars Fluagaard Jorgensen, president and CEO of Novo Nordisk, said in a press release. “This is another sure sign of our efforts to scale up production to meet the growing global demand for our life-changing medicines and the patients of the future.”
